Answers are grounded in this paper and cite their sources.
Observational analysis reports curative potential and manageable toxicities of CAR T-cell therapy, highlighting infection concerns.
Long-term follow-up has confirmed the curative potential of CAR T-cell therapy in relapsed or refractory LBCL. Toxicities are generally manageable, and although infections remain an important cause of non-relapse mortality, standardized prophylactic approaches can mitigate risk. Advances in CAR T-cell engineering and administration are likely to enhance treatment effectiveness, expand indications, and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Litvin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: